Obermatt
See Similar Stocks →

Flags

Financial distress

Seres Therapeutics

NSQ:MCRB · US81750R2013
BiotechnologySmall

360

6
Profit price37
Cash yield1
Price/Sales1
Price/Book81
Return on Capital36
Cash Return on Capital65
Return on Equity21
Profit margins15
Accruals29
Owner Earnings Margin12
Sales growth1
Profit growth69
Reinvestment1
Price momentum16
Debt load12
Refinancing11
Debt Payback1
Liquidity—
Analyst ratings100
Opinion Changes50
Price Target Upside85
Market mood1
Value Creation2/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Seres Therapeutics doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Based on 4/5 components.

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGS
Founded2010
Employees140
Websiteserestherapeutics.com
ISINUS81750R2013
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
Infectious DiseasesChronic DiseasesInflammationGastroenterologyImmunologyHepatologyBiopharmaBiotechnologyHealth CareTherapeutics

Description

Seres Therapeutics, Inc. operates as a clinical-stage company focus on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. The company led the successful development and approval of VOWST, the first FDA…

Analysis

Weak and unloved

Seres Therapeutics, Inc. is weak and unloved: below-average business metrics and a price that reflects that disappointment.

Valuation data is not available for this company.

The trajectory is tepid and the balance sheet is stretched. The company scores 2/20 on our value-creation score: not creating value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

Similar Stocks

The companies this stock is ranked against.

Compare Seres Therapeutics with its peers
Galectin Therapeutics
NAQ:GALT
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Incyte
NSQ:INCY
95
CountryUSA
IndustryBiotechnology
SizeLarge
Full Stock Analysis →
Voyager Therapeutics
NSQ:VYGR
49
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Immunic
NAQ:IMUX
38
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Invivyd
NMQ:IVVD
40
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Syndax Pharmaceuticals
NSQ:SNDX
59
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →